TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1584-1594

  Jang, E J ^a   Jeong, H ^a   Kang, J O ^a   Kim, N J ^b   Kim, M S ^b   Choi, S H ^b   Yoo, S E ^b   Hong, J H ^c   Bae, M A ^b   Hwang, E S ^a  

^a Ewha Womans University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Korea University   (South Korea)

Author keywords

osteoblast; PPAR ; RUNX2; TAZ; TM 25659

Indexed keywords

2 BUTYL 5 METHYL 6 (PYRIDINE 3 YL) 3 [2' (1H TETRAZOLE 5 YL) BIPHENYL 4 YLMETHYL] 3H IMIDAZOL[4,5 B]PYRIDINE; BONE DENSITY CONSERVATION AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION COACTIVATOR PDZ BINDING MOTIF; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WEIGHT REDUCTION;

3T3-L1 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOCYTES; ADIPOGENESIS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BONE RESORPTION; CELL DIFFERENTIATION; CELL NUCLEUS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; COS CELLS; HEK293 CELLS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOGENESIS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SMALL MOLECULE LIBRARIES; TETRAZOLES; WEIGHT GAIN;

EID: 84863134812     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01664.x     Document Type: Article

References (45)

1. Bedford MT, Sarbassova D, Xu J, Leder P, Yaffe MB, (2000). A novel pro-Arg motif recognized by WW domains. J Biol Chem 275: 10359-10369.
2. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al,. (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758.
3. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al,. (2008). A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68: 2592-2598.
4. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W, (2009). TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 284: 14347-14358.
5. Chan SW, Lim CJ, Huang C, Chong YF, Gunaratne HJ, Hogue KA, et al,. (2011). WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 30: 600-610.
6. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA, (1994). Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800.
7. Chen Y, Heiman ML, (2001). Increased weight gain after ovariectomy is not a consequence of leptin resistance. Am J Physiol Endocrinol Metab 280: E315-E322.
8. Claessens F, Gewirth DT, (2004). DNA recognition by nuclear receptors. Essays Biochem 40: 59-72.
9. Clevenger CV, (2003). Nuclear localization and function of polypeptide ligands and their receptors: a new paradigm for hormone specificity within the mammary gland? Breast Cancer Res 5: 181-187.
10. Fu H, Subramanian RR, Masters SC, (2000). 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617-647.
11. Harada S, Rodan GA, (2003). Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
12. Hong JH, Yaffe MB, (2006). TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 5: 176-179.
13. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al,. (2005). TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309: 1074-1078.
14. Ito Y, (2004). Oncogenic potential of the RUNX gene family: 'overview. Oncogene 23: 4198-4208.
15. Jans DA, (1994). Nuclear signaling pathways for polypeptide ligands and their membrane receptors? Faseb J 8: 841-847.
16. Jeong H, Bae S, An SY, Byun MR, Hwang JH, Yaffe MB, et al,. (2010). TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. Faseb J 24: 3310-3320.
17. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et al,. (2000). TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19: 6778-6791.
18. Kim M-S, Park J-S, Jang S-M, Lee BH, Ahn S-H AJH, et al,. (2011). Determination of a dipeptidyl peptidase IV agonist, [beta]-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography- tandem mass spectrometry. J Pharm Biomed Anal 55: 1083-1088.
19. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al,. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
20. Kuroda R, Cutbush S, Neidle S, Leung OT, (1985). Structural studies on some tamoxifen derivatives. J Med Chem 28: 1497-1503.
21. Lai D, Ho KC, Hao Y, Yang X, (2011). Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 71: 2728-2738.
22. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et al,. (2008). TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28: 2426-2436.
23. Lu PJ, Zhou XZ, Shen M, Lu KP, (1999). Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283: 1325-1328.
24. MacLean HE, Warne GL, Zajac JD, (1997). Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 62: 233-242.
25. Murakami M, Nakagawa M, Olson EN, Nakagawa O, (2005). A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA 102: 18034-18039.
26. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al,. (1996). Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18: 9-14.
27. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al,. (2000). Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604-610.
28. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al,. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
29. Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M, (2004). TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem 279: 17384-17390.
30. Ray S, Tandon A, Dwivedy I, Wilson SR, O'Neil JP, Katzenellenbogen JA, (1994). An X-ray crystallographic study of the nonsteroidal contraceptive agent centchroman. J Med Chem 37: 696-700.
31. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al,. (1999). PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617.
32. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, et al,. (2000). Inhibition of adipogenesis by Wnt signaling. Science 289: 950-953.
33. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al,. (1998). Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339: 292-299.
34. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ, (1993). Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 2004-2011.
35. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al,. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
36. Smith CL, O'Malley BW, (2004). Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71.
37. Vitte C, Fleisch H, Guenther HL, (1996). Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324-2333.
38. Wang K, Degerny C, Xu M, Yang XJ, (2009). YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 87: 77-91.
39. Wang CZ, Chen SM, Chen CH, Wang CK, Wang GJ, Chang JK, et al,. (2010). The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. Biomaterials 31: 8674-8683.
40. Watts NB, Diab DL, (2010). Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95: 1555-1565.
41. Wezeman FH, Emanuele MA, Moskal SF, Steiner J, Lapaglia N, (2000). Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat. J Bone Miner Res 15: 2033-2041.
42. Won HY, Lee J-A, Park ZS, Song JS, Kim HY, Jang S-M, et al,. (2011). Prominent Bone Loss Mediated by RANKL and IL-17 Produced by CD4+ T Cells in TallyHo/JngJ Mice. PLoS ONE 6: e18168.
43. Yoo SE, Kim SK, Lee SH, Yi KY, Lee DW, (1999). A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists. Bioorg Med Chem 7: 2971-2976.
44. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al,. (2009). TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 284: 13355-13362.
45. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X, (2011). TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30: 2181-2186.